

Peak Info	RT (min)	Area %	Area	Height
Number				
1	4.7	49.7448	3845.2008	365.9276
2	5.76	50.2552	3884.6553	284.9271

FIG. 1A


Single Absorbance
RT: Ret Time
A%: Area Perc
A:Area
PN: Peak Name
RT: 4.89 A
Absorbance(mAU)
250
200
150
100
50
0
-50
0
1
2
3
4
5
6
7
8
Elapsed Time(min)
Absorbance at 254nm
Peak Info
Number
RT (min)
Area %
Area
Height
1
4.89
100
2551.5441
217.4787

FIG. 1B


Single Absorbance
RT: Ret Time
A%: Area Perc
A:Area
PN: Peak Name
RT: 6.03 A:
Absorbance(mAU)
180
160
140
120
100
80
60
40
20
0
-20
0
1
2
3
4
5
6
7
8
Elapsed Time(min)
Absorbance at 254nm
Peak Info
Number
RT (min)
Area %
Area
Height
1
6.03
100
2219.2723
154.9745

FIG. 1C


AKR1C3
%Remaining
100%
80%
60%
40%
20%
0%
0
20
40
60
80
100
120
Time, min
TH2870-1
Progesterone-1
TH2870-2
Progesterone-2

FIG. 2


AKR1C3 expression in liver cancer cell lines
M
C3A
JHH-7
PLC/PRF/6
8K-HEP-1
LIC-0903
LIXC-002
LIXC-003
LIXC-004
LIXC-008
LIXC-011
LIXC-012
LIXC-068
LIXC-088
M
43 kDa
34 kDa
55 kDa
AKR1C3
Tubulin
M
C3A
HCCC 9810
Hep3B 2.1-7
HepG2
HLE
HLF
HuCC T1
8NU-182
8NU-387
8NU-398
8NU-423
8NU-449
8NU-476
M
43 kDa
34 kDa
55 kDa
AKR1C3
Tubulin

FIG. 3


M
22RV1
DU 145
LNCap
MDA-PCa-2b
NCI-H660
PC-3
VCap
M
AKR1C3
High exposure
AKR1C3
Tubulin
43 kDa
34 kDa
55 kDa

FIG. 4


Average body weight in each group
Body weight (g)
25.00
20.00
15.00
10.00
5.00
0.00
day0
day4
day7
day11
day14
day18
day21
day25
day28
day32
day35
day39
day42
day46
day49
Time (day)
Saline
Sorafenib
TH3424-2.5mg/kg
TH3424-5mg/kg

FIG. 5



FIG. 6


Tumor growth curves in each group
Saline
Sorafenib
TH3424-2.5mg/kg
TH3424-5mg/kg
Tumor Area (mm²)
16.00
14.00
12.00
10.00
8.00
6.00
4.00
2.00
0.00
day0
day4
day7
day11
day14
day18
day21
day25
day28
day32
day35
day39
day42
day46
day49
Time (day)

FIG. 7



FIG. 8


Average tumor weight in each group
Tumor weight (g)
0.25
0.20
0.15
0.10
0.05
0.00
Saline
Sorafenib
TH3424-2.5mg/kg
TH3424-5mg/kg

FIG. 9


Body weight curve of E0743-T1516
Group 1 vehicle
Group 2 AST-106 0.5mpk
Group 3 AST-106 1.5mpk
Group 4 AST-106 4.5mpk
bodyweight (g)
26
24
22
20
18
0
5
10
15
20
25
Days Post Treatment (D)

FIG. 10


Tumor Burden Growth Curve in peripheral blood of different group
Group 1 vehicle
Group 2 AST-106 0.5mpk
Group 3 AST-106 1.5mpk
Group 4 AST-106 4.5mpk
CD45 positive percent(%)
60
40
20
0
0
10
20
30
Days Post Treatment (D)
^

FIG. 11


Termination Point
Group 1 vehicle
Group 2 AST-106 0.5mpk
Group 3 AST-106 1.5mpk
Group 4 AST-106 4.5mpk
CD45 positive percent(%)
100
80
60
40
20
5
4
3
2
1
0
***
*
Blood
Spleen
Bone Marrow

FIG. 12